Harbin Medisan Stock Hits Day Low of CNY 9.82 Amid Price Pressure

Harbin Medisan Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 7.89%. The stock reached an intraday low of CNY 9.82, reflecting ongoing challenges within the company. Over the past year, Harbin Medisan has faced substantial difficulties, with a staggering 37.76% decrease in its stock value, contrasting sharply with the 7.41% gain of the China Shanghai Composite index during the same period. In terms of performance metrics, the company has reported negative net profit and operating cash flow, with the latest figures indicating a net profit of CNY -131.3 million and an operating cash flow of CNY -85.94 million. Additionally, net sales have shown a decline, growing at an annual rate of -11.77%. The company's market capitalization stands at CNY 1,626 million, categorizing it as a small-cap entity in the pharmaceuticals and biotechnology sector. With a return on equity of -17.46% and a price-to-book ratio of 0.92, Harbin Medisan continues to navigate a challenging financial landscape.